Look­ing for fresh start fol­low­ing a Duchenne dis­as­ter, Cataba­sis re­brands; Huadong and In­sil­i­co team up in on­col­o­gy

The lead­ers of Cataba­sis Phar­ma­ceu­ti­cals have de­creed that the biotech’s name is no more. Cataba­sis will be re­brand­ing to As­tria Ther­a­peu­tics ef­fec­tive im­me­di­ate­ly, with the com­pa­ny’s stock tick­er be­ing up­dat­ed on the Nas­daq on Thurs­day.

As­tria will drop the $CATB tick­er and trade un­der $ATXS.

The biotech is al­so re­nam­ing its lead com­pound from QLS-215 to STAR-0215, cur­rent­ly in pre­clin­i­cal de­vel­op­ment for the rare ge­net­ic dis­ease called hered­i­tary an­gioede­ma. As­tria ac­quired the pro­gram in its buy­out of Quel­lis Bio­sciences back in Jan­u­ary. That deal fol­lowed the com­plete col­lapse of their long-run­ning Duchenne MD drug, which flunked a Phase III tri­al last Oc­to­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.